In this phase 2b randomized trial supported by AMR Clinical sites, researchers evaluated the safety and immune response of co-administering a 6-valent group B Streptococcus (GBS6) vaccine with Tdap in healthy, nonpregnant women. GBS6 and Tdap were well tolerated when given together or alone, with most adverse events mild to moderate. While pertussis responses were lower with co-administration, robust antibody levels for tetanus, diphtheria, and GBS6 antigens were maintained.
Read this publication to explore:
- Safety outcomes for GBS6, Tdap, and combination groups
- Antibody responses for all GBS6 serotypes and Tdap antigens
- Implications for maternal vaccination strategies